Back To Education Zone

touchCONGRESS Expert Interviews

HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Congress 2019?



Watch expert breast cancer specialists discuss the latest data from the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, 27 September–1 October 2019, and consider what the findings may mean in clinical practice.

The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.

Learning Objectives

After participating in this learning activity, you should be able to:

  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

Please feed back on these touchCONGRESS Expert Interviews on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).